PanGen Biotech Reports Q3 2025 Results, Cumulative Sales of 10.94 Billion Won, Operating Profit of 1.91 Billion Won

- 6% YoY sales growth and 47% YoY operating profit growth -

- Sustained expansion across all business segments, Expanding into new export countries -

PanGen Biotech Inc. (CEO Jaeseung Yoon) of Huons Group announced on November 13 financial results for the three and nine months ended September 30, 2025, and provided an update on recent business progress. For the nine months ended September 30, 2025, total revenue and operating profit were 10.94 billion won and 1.91 billion won, up 6% and 47%, respectively, from the same period of 2024.

PanGen Biotech showed strong growth until the third quarter across all business segments including Erythropoietin (EPO) biosimilar and contract development organization (CDO).

In particular, for the nine months ended September 30, 2025, total revenue from EPO biosimilar for anemia treatment, recorded 6.07 billion won, up 76% from the same period of 2024.

PanGen Biotech showed continued growth in EPO biosimilar business. Overseas sales have increased in ASEAN countries, including Malaysia, Philippines and Thailand and full-scale exports have started to Saudi Arabia and Turkiye.

PanGen Biotech is continuously expanding export countries. Starting from Malaysian sales approval for EPO biosimilar in 2019, PanGen Biotech has now gained approvals in six countries and expanded EPO markets. PanGen Biotech plans to accelerate growth in EPO business as the company will soon expand into new markets in the Middle East, South America and Africa.

For the three months ended September 30, 2025, total revenue and operating profit were 4.01 billion won and 377 million won, down 12.7% and 71.7%, respectively, from the same period of 2024. This was due to the decrease in contract manufacturing organization (CMO) and CDO orders.

PanGen Biotech provides contract development and manufacturing organization (CDMO) business for biopharmaceuticals based on its expertise in developing original cell lines and establishing processes for biopharmaceutical production. PanGen Biotech’s order backlog totaled 4.57 billion won as of September 30, 2025.

CEO of PanGen Biotech, Jaeseung Yoon said, “We are committed to expanding our global and domestic revenue streams for EPO biosimilar by strengthening global marketing and accelerating our new CDMO business. PanGen Biotech will make best efforts to enhance collaboration with group companies for Huons Group to drive the global healthcare market.”